NEW YORK, Sept. 9, 2021 /PRNewswire/ — Channel Medsystems, Inc. (“Channel” or “Company”) and InnovaHealth Partners, LP (“InnovaHealth”) jointly announced that InnovaHealth has made a growth equity investment in Channel and acquired a significant interest in the Company. Channel legacy investors, including Third Point, Longwood Fund, and GPG Ventures, also participated in the financing. The growth capital will support the commercialization of Channel’s innovative Cerene® Cryotherapy Device for the treatment of heavy menstrual bleeding (“HMB”). Based in Berkeley, California, Channel is committed to bringing innovation and new technology to better serve gynecologists and women’s healthcare in the office setting.More
Next-generation technology enhances ease-of-use for physicians and streamlines manufacturability
The Company is targeting limited market introduction in Q42020 and commercial launch of the Cerene® Device in the first half of 2021
Emeryville, California, July 21, 2020 – Channel Medsystems® (“Channel”), a company dedicated to bringing innovation to the delivery of women’s healthcare, today announced that the U.S. Food and Drug Administration (FDA) recently approved the newest Cerene® Cryotherapy Device, a next-generation technology for the treatment of heavy menstrual bleeding in the office setting.More
Emeryville, California, December 18, 2019 — Channel Medsystems®, a company dedicated to bringing innovation to the delivery of women’s healthcare, today announced that its Cerene® Cryotherapy Device has received one of Popular Science’s Best of What’s New Awards for 2019. The Cerene® Cryotherapy Device was recognized for offering a new, minimally invasive alternative for the treatment of heavy menstrual bleeding that can be performed safely in a gynecologist’s office without anesthesia.
2019 marks the 32nd anniversary of Popular Science’s Annual Best of What’s New Awards, a list of 100 products and endeavors across ten categories that reflect the most important advancements in technology and innovation. Winners not only represent significant breakthroughs in their respective categories, but also promise to positively impact our lives.More
Emeryville, California, April 2, 2019. Channel Medsystems®, a company dedicated to bringing innovation to the delivery of women’s healthcare, today announced that the U.S. Food and Drug Administration (FDA) has approved the Cerene® Cryotherapy Device as a new approach to treating heavy menstrual bleeding.
The Cerene Device delivers cryotherapy to freeze the lining of the uterus in order to significantly reduce future menstrual bleeding. The unique design of the Cerene Device and use of extreme cold results in a procedure that does not require general anesthesia and can be performed in the gynecologist’s office. In contrast, heat-based endometrial ablation devices currently on the market are more often performed with general anesthesia in hospitals or surgery centers.More
Emeryville, California, August 23, 2017. Channel Medsystems, developer of an innovative, physician office-based therapy for heavy menstrual bleeding, announced today that it has secured a $14.1mm Series C-1 financing. The insider-led round included participation by Third Point Ventures, InCube Ventures, Aperture Venture Partners, Scientific Health Development, Longwood Fund, and Boston Scientific.
Channel Medsystems has developed the Cerene® Cryotherapy Device to treat heavy menstrual bleeding. Cerene allows women who are finished with childbearing to receive treatment in their gynecologist’s office, a more comfortable and less-expensive setting of care than a hospital or surgery center. The Company plans to use this funding to support initiatives leading up to anticipated FDA approval as well as initial preparation for commercial launch.More
Emeryville, California, June 26, 2017. Channel Medsystems, the developer of an innovative, physician office-based therapy for heavy menstrual bleeding, announced today that it has earned CE Mark approval, allowing the Company to initiate marketing efforts and commercialization of its Cerene Cryotherapy Device (Cerene device) in Europe. The Cerene device is intended for endometrial cryoablation in premenopausal women with heavy menstrual bleeding due to benign causes in whom childbearing is complete.More